Effects of cyclophosphamide in newly hatched chickens after inoculation with avian nephritis virus. 1990

M Narita, and H Kawamura, and K Furuta, and J Shirai, and K Nakamura
Poultry Disease Laboratory, National Institute of Animal Health, Gifu, Japan.

Effects of immunosuppression were compared in newly hatched chickens given cyclophosphamide (CY) after inoculation with avian nephritis virus (ANV). All CY-treated infected chickens died within 13 days after inoculation of the virus and had heavy urate deposits throughout the body. However, non-CY-treated infected, CY-treated noninfected, and non-CY-treated noninfected control chickens survived through the observation period. In a chronologic study, the value of serum uric acid in CY-treated infected chickens was more than 3 times higher than that in non-CY-treated infected chickens, and more than 9 times higher than in noninfected chickens. Serum uric acid values were coincident with the positive degree of ANV antigen in the tubular epithelial cells in the kidneys and with the severity of renal degeneration. Serologic and immunohistologic examinations did not reveal detectable antibody and IgG- and IgM-containing cells in the spleen and kidneys of CY-treated infected chickens. However, non-CY-treated infected chickens had an increased number of IgM- and IgG-containing cells and antibody against ANV on postinoculation day 6. These findings demonstrated that CY treatment enhanced the susceptibility of chickens to ANV infection.

UI MeSH Term Description Entries
D007165 Immunosuppression Therapy Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. Antirejection Therapy,Immunosuppression,Immunosuppressive Therapy,Anti-Rejection Therapy,Therapy, Anti-Rejection,Therapy, Antirejection,Anti Rejection Therapy,Anti-Rejection Therapies,Antirejection Therapies,Immunosuppression Therapies,Immunosuppressions,Immunosuppressive Therapies,Therapies, Immunosuppression,Therapies, Immunosuppressive,Therapy, Immunosuppression,Therapy, Immunosuppressive
D007243 Infectious bursal disease virus A species of AVIBIRNAVIRUS causing severe inflammation of the bursa of Fabricius in chickens and other fowl. Transmission is thought to be through contaminated feed or water. Vaccines have been used with varying degrees of success. Avian Nephrosis Virus,Gumboro Disease Virus,IBDV,Infectious Bursal Agent,Bursal Agent, Infectious,Bursal Disease Virus, Infectious,Avian Nephrosis Viruses,Bursal Agents, Infectious,Infectious Bursal Agents,Nephrosis Virus, Avian,Nephrosis Viruses, Avian
D011201 Poultry Diseases Diseases of birds which are raised as a source of meat or eggs for human consumption and are usually found in barnyards, hatcheries, etc. The concept is differentiated from BIRD DISEASES which is for diseases of birds not considered poultry and usually found in zoos, parks, and the wild. Disease, Poultry,Diseases, Poultry,Poultry Disease
D002645 Chickens Common name for the species Gallus gallus, the domestic fowl, in the family Phasianidae, order GALLIFORMES. It is descended from the red jungle fowl of SOUTHEAST ASIA. Gallus gallus,Gallus domesticus,Gallus gallus domesticus,Chicken
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000831 Animals, Newborn Refers to animals in the period of time just after birth. Animals, Neonatal,Animal, Neonatal,Animal, Newborn,Neonatal Animal,Neonatal Animals,Newborn Animal,Newborn Animals
D000921 Antibody-Producing Cells Cells of the lymphoid series that can react with antigen to produce specific cell products called antibodies. Various cell subpopulations, often B-lymphocytes, can be defined, based on the different classes of immunoglobulins that they synthesize. Antibody-Producing Cell,Antibody-Secreting Cell,Antibody-Secreting Cells,Immunoglobulin-Producing Cells,Immunoglobulin-Secreting Cells,Antibody Producing Cell,Antibody Producing Cells,Antibody Secreting Cell,Antibody Secreting Cells,Cell, Antibody-Producing,Cell, Antibody-Secreting,Cell, Immunoglobulin-Producing,Cell, Immunoglobulin-Secreting,Cells, Antibody-Producing,Cells, Antibody-Secreting,Cells, Immunoglobulin-Producing,Cells, Immunoglobulin-Secreting,Immunoglobulin Producing Cells,Immunoglobulin Secreting Cells,Immunoglobulin-Producing Cell,Immunoglobulin-Secreting Cell
D000956 Antigens, Viral Substances elaborated by viruses that have antigenic activity. Viral Antigen,Viral Antigens,Antigen, Viral
D012192 Retroviridae Infections Virus diseases caused by the RETROVIRIDAE. Retrovirus Infections,Infections, Retroviridae,Infections, Retrovirus,XMRV Infection,Xenotropic MuLV-related Virus Infection,Xenotropic Murine Leukemia Virus-related Virus Infection,Infection, Retroviridae,Infection, Retrovirus,Infection, XMRV,Infections, XMRV,Retroviridae Infection,Retrovirus Infection,XMRV Infections,Xenotropic MuLV related Virus Infection,Xenotropic Murine Leukemia Virus related Virus Infection

Related Publications

M Narita, and H Kawamura, and K Furuta, and J Shirai, and K Nakamura
January 1992, Avian diseases,
M Narita, and H Kawamura, and K Furuta, and J Shirai, and K Nakamura
January 1981, Avian diseases,
M Narita, and H Kawamura, and K Furuta, and J Shirai, and K Nakamura
March 1896, Science (New York, N.Y.),
M Narita, and H Kawamura, and K Furuta, and J Shirai, and K Nakamura
January 1989, NIDA research monograph,
M Narita, and H Kawamura, and K Furuta, and J Shirai, and K Nakamura
January 1980, National Institute of Animal Health quarterly,
M Narita, and H Kawamura, and K Furuta, and J Shirai, and K Nakamura
August 1972, Brain research,
M Narita, and H Kawamura, and K Furuta, and J Shirai, and K Nakamura
October 2018, Poultry science,
M Narita, and H Kawamura, and K Furuta, and J Shirai, and K Nakamura
January 1978, Neoplasma,
M Narita, and H Kawamura, and K Furuta, and J Shirai, and K Nakamura
November 1967, Journal of the National Cancer Institute,
M Narita, and H Kawamura, and K Furuta, and J Shirai, and K Nakamura
May 2004, Journal of veterinary medicine. B, Infectious diseases and veterinary public health,
Copied contents to your clipboard!